NL-OMON43410已完成2 期
Proof-of-pharmacology clinical trial on a vaccine that elicits a protective humoral immune response against oxidized low density lipoprotein - Pneumococcal vaccine and immunity against oxidized LD
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Male, aged 18-45 without evidence of any active or chronic disease following a medical history, a complete physical examination including vital signs, 12-lead ECG, haematology, blood chemistry and urinalysis.
- •2. Able to participate and willing to give written informed consent and to comply with the study restrictions
排除标准
- •1. Subjects vaccinated with a pneumococcus vaccine
- •2. Known allergy against any of the excipients of the Prevenar vaccine.
- •3. History or symptoms of any significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder.
- •4. History of active malignancy within the last 5 years, with the exception of localized or in situ carcinoma (e.g., skin basal or squamous cell carcinoma).
- •5. Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
- •6. Clinically significant abnormalities, as judged by the investigator, in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis). In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects.
- •7. Participation in an investigational drug study within 3 months prior to screening.
- •8. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening.
- •9. Concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study.
- •10. Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non-active hay fever is acceptable).
- •11. Unwillingness or inability to comply with the study protocol for any other reason.
- •12. Active infection at the time of baseline visit, as evidence by either a body temperature >37.5 °C or CRP >10 mg/L.
研究者
相似试验
进行中（未招募）
1 期
Pneumococcal vaccine against atherosclerosisHealthy male volunteersMedDRA version: 19.0Level: LLTClassification code 10003601Term: AtherosclerosisSystem Organ Class: 100000004866EUCTR2015-005650-35-NLCentre for Human Drug Research24
已完成
不适用
Pneumococcal vaccine against atherosclerosisAtherosclerosisNL-OMON21732.A.24
进行中（未招募）
1 期
Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want to evaluate the safety and the immunogenicity of a vaccine that includes a first administration of theChAdOx1.tHIVconsvX product and a second one with MVA.tHIVconsvX in HIV-1 positive adults treated early and able to control the infection for a long time.HIV InfectionCTIS2024-514581-39-00Ospedale San Raffaele S.r.l.33
已完成
不适用
Studies on effectiveness and safety of vaccination with H5N1 prepandemic vaccines, and cross-immunity among H5N1 virusesJPRN-UMIN000024388Fujita Health University200
招募中
2 期
Clinical trial of therapeutic vaccine against HBV carriers without anti-HBV treatmentchronic hepatitis BD019694JPRN-jRCTs061210087Hiasa Yoichi200